Clinical trial · Observational
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This NIH-NCCAM funded epidemiologic research is being conducted as an observational prospective case-control study of the use of Complementary and Alternative Medicine (CAM) and Integrated Oncology (IO) and their effects on breast cancer patients in community settings. Hypothesis: IO services improve patients' quality of life and decrease cancer recurrence rates in breast cancer patients as compared to women with similar disease states and prognoses who do not receive IO care, and may or may not use CAM treatment on their own.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- IO Clinic Breast Cancer Patients
- description
- Includes patients who are receiving care for their breast cancer at participating Seattle area IO clinics.
- label
- CSS Match-Control Patients
- description
- For each IO clinic patient, an average of two (up to four) matched comparison cases will be recruited from the Washington State Cancer Surveillance System (CSS). Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.
Primary outcomes (2)
- measure
- Aim 1: Describe treatments received by breast cancer patients receiving physician level practitioner IO care and the cost of IO care.
- timeFrame
- Baseline, 6, 12, 24, 36, 48, and 60 months post study enrollment.
- description
- Will also describe how long after diagnosis women with breast cancer seek IO care and differences in IO care prescriptions associated with when, in a woman's course of treatment, she seeks care. This patient cohort will consist of all female patients with breast cancer seeking IO clinic care. Our analyses will describe how long after diagnosis women with breast cancer seek IO care and describe differences in IO care prescriptions associated with when, in a woman's course of treatment, she seeks care.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
The patients enrolled into the study will include patients who meet the following criteria: Cohort 1: IO clinic breast cancer patients 1. Confirmed breast cancer of primary breast cancer with ICD9 code of 174.x, 233.0 or V10.3 2. Female 3. ≥18 years of age 4. Can provide signed informed consent 5. 1st IO clinic visit ≤3 months prior to enrollment 6. Can read and understand the questionnaires Cohort 1A: Sub-cohort of IO clinic patients (cases) who meet the following additional criteria and for whom matched controls have been found from the CSS database. 1. ICD9 code of 174.x or 233.0 2. Primary ductal or lobular breast cancer diagnosis ≤2 years prior to 1st IO clinic visit 3. Minimum of two IO clinic visits within 7 months 4. Provided Baseline Questionnaire Cohort 2: Matched controls from CSS database for Cohort 1A patients 1. Confirmed breast cancer 2. Female 3. ≥ 18 years of age 4. Can provide informed consent
References
Publications (1)
- DERIVEDStandish LJ, Dowd F, Sweet E, Dale L, Andersen MR. Do Women With Breast Cancer Who Choose Adjunctive Integrative Oncology Care Receive Different Standard Oncologic Treatment? Integr Cancer Ther. 2018 Sep;17(3):874-884. doi: 10.1177/1534735418769007. Epub 2018 Apr 27. PMID 29701107